EMA Authorised: Micardis (telmisartan) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The EMA authorised Micardis (telmisartan) by Boehringer Ingelheim International GmbH for use in hypertension, with a decision dated 18 February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Micardis (telmisartan)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Boehringer Ingelheim International GmbH. Decision date: 18/02/2026